Conformal Medical

09/04/2025

Living with non-valvular AFib?
You may be a candidate for the CONFORM Pivotal Trial with the CLAAS® AcuFORM™ Implant. The CONFORM trial offers patients an alternative to long-term use of blood thinners by permanently sealing off the left atrial appendage (LAA) — a common source of blood clots that can lead to stroke.

Discuss with your doctor to see what treatment option is best for you.

Visit CONFORMTrial.com to learn more and to find a participating center near you.

The CLAAS AcuFORM System is an investigational device in the United States, which means that it has not yet been approved by the Food and Drug Administration (FDA) for sale in the U.S.

The risks of delivery of the CLAAS Implant are similar to those of other procedures that require a transseptal puncture and transcatheter delivery of an implant through the venous system, across the interatrial septum, and into the left atrium using a specialized catheter (e.g., EP procedures and/or other LAA devices such as Watchman).

CAUTION: Investigational Device. The CLAAS System is limited by Federal (or United States) law to investigational use.

09/04/2025

Living with non-valvular AFib?
You may be a candidate for the CONFORM Pivotal Trial with the CLAAS® AcuFORM™ Implant. When blood thinners (anticoagulants) aren’t enough or cause issues that affect your quality of life, left atrial appendage occlusion (LAAO) therapy might be an option.

Discuss with your doctor to see what treatment option is best for you.

Visit CONFORMTrial.com to learn more and to find a participating center near you.

The CLAAS AcuFORM System is an investigational device in the United States, which means that it has not yet been approved by the Food and Drug Administration (FDA) for sale in the U.S.

The risks of delivery of the CLAAS Implant are similar to those of other procedures that require a transseptal puncture and transcatheter delivery of an implant through the venous system, across the interatrial septum, and into the left atrium using a specialized catheter (e.g., EP procedures and/or other LAA devices such as Watchman).

CAUTION: Investigational Device. The CLAAS System is limited by Federal (or United States) law to investigational use.

05/14/2025

A new website is now available for the CONFORM Pivotal Trial evaluating the CLAAS® AcuFORM™ Left Atrial Appendage Occlusion Technology: www.conformtrial.com.

This site provides information for individuals living with non-valvular atrial fibrillation (AFib) who may be interested in an alternative to long-term blood thinners.

Visitors can learn about the study, review eligibility criteria, and find out if there is a participating clinical trial site nearby.

To explore participation or share with someone who may benefit, visit:
www.conformtrial.com



CAUTION: Investigational Device
The CLAAS System is limited by Federal (or United States) law to investigational use

The FDA approved CONFORM Pivotal Trial is evaluating the CLAAS® AcuFORM™ Implant compared to other commercially available Left Atrial Appendage Occlusion (LAAO) devices in patients with non-valvular Atrial Fibrillation (AFib).

02/26/2024

Last week, we hosted our second CONFORM Research Coordinator Meeting, bringing together a community of dedicated partners in the pursuit of advancing the science of LAAO therapy.

It was an incredible opportunity to connect, engage, and educate one another on best practices, tips & tricks, and enrollment experiences. A huge shoutout and thank you to all our amazing Research Coordinators for their active participation!

Your passion and commitment drive us forward.

To learn more about Conformal Medical, visit: https://lnkd.in/e8PSeVv8

02/12/2024

February is American Heart Month.
This is your reminder to schedule regular check-ups with your healthcare provider to monitor and manage your heart health. Early detection and intervention can make a significant difference.

For those living with Afib and who are taking anticoagulants to reduce your risk of stroke, you have options. Learn how LAAO procedures may be an option for you visit, https://www.bswhealth.com/blog/laao-procedure-for-afib-an-alternative-to-blood-thinners

At Conformal Medical, we are developing the next generation of LAAO technology. To learn about the CONFORM Pivotal Trial and the CLAAS® System, visit https://conformalmedical.com/patient/afib-and-stroke



CAUTION: Investigational Device
The CLAAS System is limited by Federal (or United States) law to investigational use.

Conformal is a privately held medical device company that designed the CLAAS System to seal the LAA to reduce the risk of stroke, without the need for anticoagulants.

01/18/2024

CONFORM Clinical Trial is enrolling now!

The CONFORM Pivotal Trial is evaluating the CLAAS® System compared to other commercially available LAAO devices in patients with non-valvular Afib.

Learn more about the trial and if it is right for you?

The CLAAS System is limited by Federal (or United States) law to investigational use.

https://conformalmedical.com/patient/enroll-in-trial

01/18/2024

In 2022, Conformal Medical Announces Launch of CONFORM Pivotal Trial Study to support U.S. FDA approval of the novel CLAAS® implant for left atrial appendage occlusion (LAAO) and stroke prevention.

Read the press release here: https://conformalmedical.com/company/news/conformal-medical-announces-launch-of-conform-pivotal-trial

The CLAAS System is limited by Federal (or United States) law to investigational use.

Conformal is a privately held medical device company that designed the CLAAS System to seal the LAA to reduce the risk of stroke, without the need for anticoagulants.

01/18/2024

CLAAS® System A NEW DEVICE FOR TREATING THE LEFT ATRIAL APPENDAGE

The CLAAS® System is a foam device designed to fit in each patient’s anatomy and seal the LAA to reduce the risk of stroke without the need for anticoagulants. The device is permanently placed in the heart by your physician during a single procedure.

Learn how the it works.

The CLAAS System is limited by Federal (or United States) law to investigational use.

01/18/2024

Afib, or an irregular heartbeat, can cause blood to pool in a small pouch off the upper left chamber of the heart, known as the . This pooling can cause the formation of blood clots which may lead to stroke.

The CLAAS® System is a foam device designed to fit in each patient’s anatomy and seal the LAA to reduce the risk of stroke without the need for anticoagulants. The device is permanently placed in the heart by your physician during a single procedure.



The CLAAS System is limited by Federal (or United States) law to investigational use.

01/18/2024

Conformal Medical, Inc., a privately held medical device company developing next generation left atrial appendage closure (LAAC) technology, today announced positive clinical data from First-in-Human studies performed in the U.S. and Prague. Data were presented at the 32nd Transcatheter Cardiovascul...